

## IN VITRO STUDIES ON THE ANTIDIABETIC ACTIVITY OF 2-THIOHYDANTOIN USING $\alpha$ -amylase AND $\alpha$ -GLUCOSIDASE

UMA S<sup>1</sup>, DEVIKA PT<sup>2\*</sup>

<sup>1</sup>Department of Biotechnology, Dwaraka Doss Goverdhan Doss Vaishnav College, Chennai, Tamil Nadu, India. <sup>2</sup>Department of Biochemistry, Mohamed Sathak College of Arts and Science, Tamil Nadu, India. Email: devikabio@rediffmail.com

Received: 12 August 2019, Revised and Accepted: 29 October 2019

### ABSTRACT

**Objective:** The aim of the present study was to investigate the inhibitory effect of 2-thiohydantoin on the enzymes  $\alpha$ -amylase and  $\alpha$ -glucosidase *in vitro* as an antidiabetic therapeutic approach to reduce gastrointestinal glucose production.

**Methods:** Antidiabetic activity of the compound, 2-thiohydantoin was measured using the enzymes  $\alpha$ -amylase and  $\alpha$ -glucosidase.

**Results:** Half-maximal inhibitory concentration of the antidiabetic  $\alpha$ -amylase was found to be 410.35  $\mu$ g/ml and  $\alpha$ -glucosidase was found to be 356.33  $\mu$ g/ml, respectively.

**Conclusion:** The result obtained in the *in vitro* enzyme assay suggests the antidiabetic activity of 2-thiohydantoin.

**Keywords:** 2-thiohydantoin,  $\alpha$ -amylase,  $\alpha$ -glucosidase, Antidiabetic activity.

© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>) DOI: <http://dx.doi.org/10.22159/ajpcr.2019.v12i12.35320>

### INTRODUCTION

Diabetes mellitus is a metabolic disorder which affects the blood glucose level in our body. This disease can be considered as the epidemic of the century. At present, an estimated 150 million people worldwide have diabetes and that this will increase 220 million by 2010 and 300 million by 2025 [1]. Globally, type II diabetes (non-insulin-dependent diabetes mellitus) accounts for >90% of the cases [2]. Postprandial hyperglycemia is an important contributing factor for the development of diabetic complications (Monami *et al.*, 2013) [3]. It plays an important role in the development of type II diabetes mellitus and its associated chronic complications such as micro- and macro-vascular disorders (neuropathy, cardiovascular, and cerebrovascular diseases) (Boutati and Raptis, 2004) [4]. Postprandial hyperglycemia depends on the absorbed monosaccharides such as glucose. It can be regulated by carbohydrate hydrolyzing enzymes such as  $\alpha$ -amylase and  $\alpha$ -glucosidase. Inhibition of these enzymes prolongs overall carbohydrate digestion time causing reduction in the rate of glucose absorption and prevents hyperglycemia (Boutati and Raptis 2004) [5]. Antihyperglycemic agents are used to control blood glucose levels within the normal range. However, these agents are associated with various side effects and limited efficacy [1]. Many compounds were found to have the inhibitory effect on  $\alpha$ -amylase and  $\alpha$ -glucosidase. 2-thiohydantoin is a heterocyclic organic compound which possesses a wide range of other pharmaceutical properties including antitumor, anti-inflammatory, anti-HIV, hypolipidemic, antiarrhythmic, and antihypertensive effects [6]. The aim of the present study is to investigate the antidiabetic activity of 2-thiohydantoin on the mammalian carbohydrate-digesting enzymes such as pancreatic  $\alpha$ -amylase and intestinal  $\alpha$ -glucosidase by determining their inhibitory potential.

### METHODS

#### Sample

The synthetic compound, 2-thiohydantoin (C<sub>3</sub>H<sub>4</sub>N<sub>2</sub>OS) is available as brown crystalline powder having molecular weight of 116.14. The drug was purchased from SIGMA-ALDRICH, Germany. The parent compound hydantoin was first isolated in 1861 by Adolf von Baeyer in the course of

his study of uric acid. The derivatives of 2-thiohydantoin are produced by heating a mixture of thiourea and alpha-amino acid. The compound was soluble in dimethyl sulfoxide.

#### Chemicals and reagents

Sodium phosphate buffer, 3, 5-dinitrosalicylic acid, PNPG, starch solution, sodium carbonate,  $\alpha$ -amylase,  $\alpha$ -glucosidase, acarbose, and other chemicals needed for this assay were received from Royal Bioresearch Institute, Tamil Nadu, India.

#### $\alpha$ -amylase inhibition assay

The inhibitory activity of the enzyme,  $\alpha$ -amylase was performed using standard methods with slight modifications [7]. Acarbose was used as a standard drug. About 100–500  $\mu$ g/ml of the test sample, 2-thiohydantoin was taken in test tubes. About 250  $\mu$ l of  $\alpha$ -amylase (1 mg/ml) in 0.2 M sodium phosphate buffer (pH 6.9) was added to each of the test tube and was incubated at 37°C for 20 min. Then, 250  $\mu$ l of 0.5% starch solution in 0.2 M sodium phosphate buffer (pH 6.9) was added to each of the test tube. The reaction mixtures were then incubated at 37°C for 15 min. The reaction was stopped with the addition of 1 ml of 3, 5-dinitrosalicylic acid. The test tubes were then incubated in a boiling water bath at 100°C for 10 min and then cooled to room temperature. The reaction mixture was then diluted to 10 ml using distilled water and absorbance was measured at 595 nm using ultraviolet (UV)-visible spectrophotometer. The inhibitory activity of  $\alpha$ -amylase was calculated using the following formula:

$$\% \text{ inhibition of } \alpha\text{-amylase} = (A \text{ of test} - A \text{ of control}) / A \text{ of control} \times 100,$$

Where, A indicates the absorbance value.

#### $\alpha$ -glucosidase inhibition assay

The inhibitory activity of the enzyme,  $\alpha$ -glucosidase was performed using standard methods [8,9]. Acarbose was used as a standard drug. About 50  $\mu$ l of the enzyme,  $\alpha$ -glucosidase was mixed with the test sample, 2-thiohydantoin (100–500  $\mu$ g/ml) taken in different test tubes. The tubes were vortexed and incubated at 37°C for 30 min. About 800  $\mu$ l of 0.1 M sodium carbonate was added. Absorbance was measured at 405 nm using UV-visible spectrophotometer [10].

The inhibitory activity of  $\alpha$ -glucosidase was calculated using the following formula:

$$\% \text{ inhibition of } \alpha\text{-glucosidase} = (A \text{ of test} - A \text{ of control}) / A \text{ of control} \times 100,$$

Where, A indicates the absorbance value.

**Table 1: IC<sub>50</sub> value for acarbose in  $\alpha$ -amylase inhibitory assay of *in vitro* antidiabetic activity**

S. No.	Concentration of the standard (acarbose) ( $\mu\text{g/ml}$ )	% of $\alpha$ -amylase inhibition	IC <sub>50</sub> ( $\mu\text{g/mL}$ )
1.	100	4.1	427.51
2.	200	17.8	
3.	300	32.3	
4.	400	45.2	
5.	500	61.0	

IC<sub>50</sub>: Half-maximal inhibitory concentration

**Table 2: IC<sub>50</sub> value for 2-thiohydantoin in  $\alpha$ -amylase inhibitory assay of *in vitro* antidiabetic activity**

S. No.	Concentration of the test sample (2-thiohydantoin) ( $\mu\text{g/ml}$ )	% of $\alpha$ -amylase inhibition	IC <sub>50</sub> ( $\mu\text{g/mL}$ )
1.	100	5.2	410.35
2.	200	21.7	
3.	300	33.3	
4.	400	43.7	
5.	500	51.3	

IC<sub>50</sub>: Half-maximal inhibitory concentration

The concentration of the test sample, 2-thiohydantoin to inhibit half (50%) of  $\alpha$ -glucosidase activity is known as the half-maximal inhibitory concentration (IC<sub>50</sub>) value.

#### Statistical analysis

The results were expressed as mean values and standard deviation. Linear regression analysis was used to calculate IC<sub>50</sub> value.


#### RESULTS

$\alpha$ -amylase inhibitory activity for standard drug, acarbose and the test sample, 2-thiohydantoin were presented in Tables 1 and 2 respectively. The inhibition of the enzyme,  $\alpha$ -amylase shows optimum activity of 61% at a maximum concentration of the standard drug, acarbose (500  $\mu\text{g/ml}$ ) was shown in Fig. 1a. The inhibition of the enzyme,  $\alpha$ -amylase shows optimum activity of 51.3% at a maximum concentration of the test drug, 2-thiohydantoin (500  $\mu\text{g/ml}$ ) was shown in Fig. 1b. The IC<sub>50</sub> values for the standard drug, Acarbose and the test sample, 2-thiohydantoin and was found to be 427.51 and 410.35 respectively.


$\alpha$ -glucosidase inhibitory activity for standard drug, acarbose and the test sample, 2-thiohydantoin were presented in Tables 1 and 2 respectively. The inhibition of the enzyme,  $\alpha$ -glucosidase shows optimum activity of 80.01% at a maximum concentration of the standard drug, acarbose (500  $\mu\text{g/ml}$ ) was shown in Fig. 1a. The inhibition of the enzyme,  $\alpha$ -glucosidase shows optimum activity of 56% at a maximum concentration of the test drug, 2-thiohydantoin (500  $\mu\text{g/ml}$ ) was shown in Fig. 1b. The IC<sub>50</sub> values for the standard drug, Acarbose and the test sample, 2-thiohydantoin and was found to be 263.33 and 356.33 respectively.

#### DISCUSSION

The treatment strategy of diabetes is controlling postprandial hyperglycemia after the consumption of the meals. As the digestion



**Fig. 1: (a and b) Half-maximal inhibitory concentration value for 2-thiohydantoin in  $\alpha$ -amylase inhibitory assay of *in vitro* antidiabetic activity**



**Fig. 2: (a and b) Half-maximal inhibitory concentration value for 2-thiohydantoin in  $\alpha$ -glucosidase inhibitory assay of *in vitro* antidiabetic activity**

**Table 3: IC<sub>50</sub> value for acarbose in  $\alpha$ -glucosidase inhibitory assay of *in vitro* antidiabetic activity**

S. No.	Concentration of the standard (acarbose) ( $\mu\text{g/ml}$ )	% of $\alpha$ -glucosidase inhibition	IC <sub>50</sub> ( $\mu\text{g/mL}$ )
1.	100	28.2	263.33
2.	200	44.6	
3.	300	56.1	
4.	400	64.3	
5.	500	80.1	

IC<sub>50</sub>: Half-maximal inhibitory concentration**Table 4: IC<sub>50</sub> value for 2-thiohydantoin in  $\alpha$ -glucosidase inhibitory assay of *in vitro* antidiabetic activity**

S. No.	Concentration of 2-thiohydantoin ( $\mu\text{g/ml}$ )	% of $\alpha$ -glucosidase inhibition	IC <sub>50</sub> ( $\mu\text{g/mL}$ )
1.	100	16.46	356.33
2.	200	32.12	
3.	300	40.05	
4.	400	56.01	
5.	500	69.01	

IC<sub>50</sub>: Half-maximal inhibitory concentration

of carbohydrates starts from the salivary amylase, polysaccharides such as starch and glycogen are broken down to disaccharides. Then, the pancreatic amylase and  $\alpha$ -glucosidase break down the disaccharides into monosaccharide such as glucose increasing the blood glucose level, leading to postprandial hyperglycemia. The results of the present study indicate that the synthetic drug, 2-thiohydantoin shows  $\alpha$ -amylase and  $\alpha$ -glucosidase inhibitory activity. Amylase is present in saliva and pancreatic juices. Amylase and glucosidase break down the glycogen and starch present in the meals to dextrins which is further broken down into glucose units, leading to postprandial hyperglycemia.  $\alpha$ -amylase and glucosidase inhibition provides a therapeutic approach to control the glucose level in the blood preventing hyperglycemia. IC<sub>50</sub> value of 2-thiohydantoin shows significant glycoside enzyme inhibitory activity.

## CONCLUSION

This study shows that 2-thiohydantoin has antidiabetic potential by inhibiting the glucose hydrolysing enzymes such  $\alpha$ -amylase and

$\alpha$ -glucosidase and can be used as a therapeutic agent for treating diabetes.

## AUTHORS' CONTRIBUTIONS

Principal author: Performed collection of sample, extraction, analysis, interpreted data, wrote the manuscript, and acted as corresponding author.

Coauthor contribution: Supervised the development of work and helped in the evaluation of the manuscript.

## CONFLICTS OF INTEREST

There are no conflicts of interest. This article is the independent work of the authors. This article does not contain any studies with human or animal subjects performed by the any of the authors.

## REFERENCES

- Arce FV Jr., Concepcion JE, Mayol KM, See GL. *In vitro*  $\alpha$ -amylase and  $\alpha$ -glucosidase inhibition activity of tabing *Abutilon indicum* (Linn 1836) root extracts. *Int J Toxicol Pharmacol Res* 2016;8:391-6.
- Li Y, Wen S, Kota BP, Peng G, Li GQ, Yamahara J, et al. *Punica granatum* flower extract, a potent  $\alpha$ -glucosidase inhibitor, improves postprandial hyperglycemia in zucker diabetic fatty rats. *J Ethnopharmacol* 2005;99:239-44.
- Tiwari AK, Rao JM. Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospects. *Curr Sci* 2002;83:30-8.
- Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials. *Diabetes Obes Metab* 2013;15:112-20.
- Boutati EI, Raptis SA. Postprandial hyperglycaemia in Type 2 diabetes: Pathophysiological aspects, teleological notions and flags for clinical practice. *Diabetes Metab Res Rev* 2004;20 Suppl 2:S13-23.
- Wang ZD, Sheikh SO, Zhang Y. A simple synthesis of 2-thiohydantoins. *Molecules* 2006;11:739-50.
- Hansawasdi C, Kawabata J, Kasai T.  $\alpha$ -amylase inhibitors from roselle (*Hibiscus sabdariffa* Linn.) tea. *Biosci Biotechnol Biochem* 2000;64:1041-3.
- Ramprasad R, Madhusudhan S, Dhanapal CK. *In vitro*  $\alpha$ -glucosidase inhibitory activities of ethonolic extract of *Oldenlandia corymbosa*. *Der Pharm Chem* 2016;8:135-9.
- Reka P, Banu T, Seethalakshmi M.  $\alpha$  amylase and  $\alpha$  glucosidase inhibition activity of selected edible seaweeds from South coast area of India. *Int J Pharm Pharm Sci* 2017;9:64-8.
- Jaiswal P, Kumar P.  $\alpha$  amylase inhibitory activity of different extract of bark of *Albizia lebbek* (L.) benth. *Int J Pharm Pharm Sci* 2017;9:119-22.